Vaccines Against Salmonella Typhi: a phase IIb, single centre, observer-blind, randomised controlled trial to assess the immunogenicity and protective efficacy of Vi conjugated (Vi-TCV) and unconjugated (Vi-PS) polysaccharide vaccines in preventing typhoid infection compared to a control vaccine (meningococcal ACWY), using a human challenge model of typhoid infection

Trial Profile

Vaccines Against Salmonella Typhi: a phase IIb, single centre, observer-blind, randomised controlled trial to assess the immunogenicity and protective efficacy of Vi conjugated (Vi-TCV) and unconjugated (Vi-PS) polysaccharide vaccines in preventing typhoid infection compared to a control vaccine (meningococcal ACWY), using a human challenge model of typhoid infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Typhoid vaccine Vi conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate; Typhoid vaccine Vi-polysaccharide
  • Indications Typhoid
  • Focus Therapeutic Use
  • Acronyms VAST
  • Most Recent Events

    • 03 Oct 2017 New source identified and integrated (ClinicalTrials.gov NCT02324751).
    • 03 Oct 2017 Results assessing efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi, were published in the Lancet.
    • 09 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top